Evaluating covid-19 vaccine efficacy and safety in the post-authorisation phase
- PMID: 34949587
- DOI: 10.1136/bmj-2021-067570
Evaluating covid-19 vaccine efficacy and safety in the post-authorisation phase
Conflict of interest statement
Competing interests: We have read and understood BMJ policy on declaration of interests and have the following interests to declare: PD has received travel funds from the European Respiratory Society (2012) and Uppsala Monitoring Center (2018); grants from the FDA (through University of Maryland M-CERSI; 2020), Laura and John Arnold Foundation (2017-22), American Association of Colleges of Pharmacy (2015), Patient-Centred Outcomes Research Institute (2014-16), Cochrane Methods Innovations Fund (2016-18), and UK National Institute for Health Research (2011-14); was an unpaid IMEDS steering committee member at the Reagan-Udall Foundation for the FDA (2016-2020), and is an editor at The BMJ. All other authors declare none.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical